Chromophobe renal cell carcinoma (CRCC) is the third most common subtype of renal
cell carcinoma (RCC).
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.J Urol. 2010; 183: 1309-1315
- Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.Am J Surg Pathol. 2008; 32: 1822-1834
- Nivolumab versus everolimus in advanced renal-cell carcinoma.N Engl J Med. 2015; 373: 1803-1813
- Pathobiology and prognosis of chromophobe renal cell carcinoma.Urol Oncol. 2008; 26: 604-609
- Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features.Eur Urol. 2015; 68: 2015-2017
- Long-term response to nivolumab and acute renal failure in a patient with metastatic papillary renal cell carcinoma and a PD-L1 tumor expression increased with sunitinib therapy: a case report.Front Oncol. 2016; 6: 250
- Anti-programmed death receptor 1 blockade induces clinical response in a patient with metastatic collecting duct carcinoma.Clin Genitourin Cancer. 2016; 14: e431-e434
- Unclassified renal cell carcinoma with significant response to nivolumab.Clin Genitourin Cancer. 2017; 15: e517-e519
- Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: in-label but without evidence.Invest New Drugs. 2017; (Epub ahead of print)http://dx.doi.org/10.1007/s10637-017-0469-5
- PD-L1 expression in non-clear cell renal cell carcinoma.Ann Oncol. 2014; 25: 2178-2184
Article info
Publication history
Published online: June 02, 2017
Accepted:
May 25,
2017
Received:
May 17,
2017
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
